In this episode of the Lupus Foundation of America podcast, Jaren Crump sits down with Dr. Luís Inês, rheumatologist and President of the European Lupus Society, about new research that could change how doctors understand and treat severe lupus. Dr. Inês explains how an evaluation tool known as SLE-DAS, makes it easier for clinicians to measure severe lupus disease activity — and why that matters for improving treatment decisions, quality of life, and long-term health.

Read the paper published in LSM: https://doi.org/10.1136/lupus-2025-001499

In this episode of the Lupus Science and Medicine Podcast, host Dr. Anna Wolska speaks with Dr. Amerie Grammer about how genetic breakthroughs are paving the way for personalized lupus care. Researchers have identified distinct “genetic endotypes,” patterns of gene activity that explain why lupus affects people differently, including symptoms like kidney disease. These insights could one day enable more precise, targeted treatments. Tune in as we unpack what genetic endotypes are, what they reveal about lupus, and how this research brings us closer to truly individualized care for everyone living with the disease.

Read the paper published in LSM: https://doi.org/10.1136/lupus-2025-001526

In this podcast, Dr. Anna Wolska sits down with Dr. Eric Morand to discuss a groundbreaking effort to improve how lupus treatment success is measured in clinical trials. Dr. Morand explains why existing tools weren’t designed for tracking treatment response and describes a rigorous, patient-inclusive Delphi process that narrowed dozens of possible disease aspects down to eight meaningful domains. By involving patients at every step, the new measure focuses on what patients truly feel and function. Early work on defining precise assessments for each domain is underway, with practical use in trials expected by 2026, promising clearer results and faster access to new lupus therapies.

Read the paper published in LSM - https://doi.org/10.1136/lupus-2024-001484

Lupus nephritis, affecting nearly half of lupus patients, can cause severe kidney damage. Traditionally, high-dose glucocorticoids (~1 mg per kg prednisone) have been used despite significant side effects. In this episode, host Anna Wolska speaks with Dr. Amit Saxena, a rheumatologist and Associate Professor at NYU Langone Health, about his recent research on the use of glucocorticoids in treating kidney disease in lupus. His study pooled standard-of-care arms from several major clinical trials to compare the efficacy and safety of lower versus higher oral glucocorticoid doses—administered after an initial IV steroid pulse—in treating lupus nephritis.

Read the article published in LSM - https://doi.org/10.1136/lupus-2024-001351

Join Dr. Anna Wolska from the Lupus Foundation of America as she talks with Dr. Jim Oates about his recently published study in Lupus Science & Medicine on validating claims-based algorithms in Medicare data to identify SLE and lupus nephritis. Dr. Oates explains how ICD-10 coding and geospatial analysis (via the Lupus Index) can help pinpoint disparities, guide clinical trial recruitment, and reveal how location affects patient outcomes. The conversation covers the varying sensitivity and specificity of different coding algorithms, potential racial differences, and how overlaying socioeconomic and environmental data can shed light on lupus prevalence and improve healthcare resource allocation.

Read the article published in LSM - https://doi.org/10.1136/lupus-2024-001329

Early reduction in proteinuria is a key predictor of improved long-term kidney health in lupus nephritis (LN). In this episode, Dr. Anna Wolska from the Lupus Foundation of America speaks with Drs. Maria Dall'Era and Anca Askanase about a new propensity analysis comparing voclosporin-based triple immunosuppressive therapy to traditional high-dose glucocorticoid regimens. They discuss findings from the AURA-LV and AURORA 1 studies, highlighting the safety benefits and earlier proteinuria reduction seen with voclosporin. Tune in to explore how these insights may shape LN treatment guidelines and improve patient outcomes.

Read the paper published in LSM: https://doi.org/10.1136/lupus-2024-001319

Join Dr. Anna Wolska and Dr. Jordan Roberts, a pediatric rheumatologist, as they explore the use of Rituximab in treating childhood-onset systemic lupus erythematosus (SLE). They discuss key factors for healthcare providers when prescribing Rituximab to children and adolescents, especially for severe cases like lupus nephritis and CNS involvement. Dr. Roberts presents recent research on Rituximab’s safety, highlighting increased infection risks and the need for targeted prevention strategies. Tune in for expert insights on the latest advancements, challenges, and future directions in pediatric lupus treatment.

Read the paper published in LSM - https://doi.org/10.1136/lupus-2024-001210

In this episode of the Lupus Science and Medicine podcast, Dr. Megan Clowse, a rheumatologist at Duke University, discusses her research on contraceptive practices in women with lupus. Drawing from the RISE Registry, Dr. Clowse explores the alignment of contraception use with 2020 ACR guidelines, uncovering gaps in documentation and prescription practices. The conversation highlights the importance of reproductive health planning, the various birth control options for women with lupus, and the need for improved patient-doctor communication to ensure safe and effective family planning. Tune in to learn more about the findings and their implications for clinical care.

Read the related paper published in LSM: https://doi.org/10.1136/lupus-2024-001192